symptoms to AIs. 51 With the increase in its use, AI-related arthralgia is emerging as a major source of symptom burden among its users, with a 28% relative increase compared with placebo. 2 Although the understanding of this symptom is extremely limited, in a recent study among 200 ambulatory breast cancer survivors (BCSs) receiving AIs, 47% reported AI-related joint pain and 44% reported AI-related stiffness. 5 Arthralgia not only impairs function 6 but also can lead to treatment discontinuation. 7 As medical science introduces life-prolonging therapies such as AIs, research is needed to identify and test effective strategies to minimize the side effects of AIs so that both the length and quality of survivorship can be enhanced. Given the extensive use of complementary therapies by BCSs, 8,9 acupuncture is promising as an acceptable nonpharmacological approach for the treatment of AIrelated arthralgia. Although the exact cause of arthralgia by AIs is unknown, one of the likely explanations is that the depleted estrogen level may decrease the generation of endogenous opioids, thereby leading to lowered pain A romatase inhibitors (AIs) have become an important standard adjuvant hormonal therapy for postmenopausal women with hormone-receptor-positive invasive breast cancer. Improvements in disease-free survival have been found in randomized controlled trials (RCTs) to be as high as 40% and greater when compared with tamoxifen. 1-4 A study by our group also demonstrated that close to half of the AI-users attributed their joint Background. Arthralgia affects postmenopausal women receiving aromatase inhibitors (AIs) for breast cancer. Given the existing evidence for electroacupuncture (EA) for treatment of osteoarthritis in the general population, this study aims to establish the feasibility of studying EA for treating AI-related arthralgia. Patients and Methods. Postmenopausal women with stage I-III breast cancer who reported AI-related arthral gia were enrolled in a single-arm feasibility trial. EA was provided twice a week for 2 weeks followed by 6 weekly treatments. The protocol was based on Chinese medicine diagnosis of "Bi" syndrome with electrostimulation of needles around the painful joint(s). Pain severity of the modified Brief Pain Inventory was used as the primary outcome. Joint stiffness, joint interference, and Patient Global Impression of Change (PGIC) were secondary outcomes. Paired t tests were used for analysis. Results. Twelve women were enrolled and all provided data for analysis. From baseline to the end of intervention, patients reported reduction in pain severity (from 5.3 to 1.9), stiffness (from 6.9 to 2.4), and joint symptom interference (from 4.7 to 0.8), all P < .001; 11/12 considered joint symptoms "very much better" based on the PGIC. Subjects also reported significant decrease in fatigue (from 4.4 to 1.9, P = .005) and anxiety (from 7.1 to 4.8, P = .01). No infection or development or worsening of lymphedema was observed. Conclusion. Preliminary data establish the feasibility of recruitm...

No abstract

Background: With rapid advances in research clinicians often struggle to remain current on evolving care guidelines as well as current National Quality Standards (NQS) relevant to breast cancer management. Adherence to NQS now drives much reimbursement for cancer center services but clinical workflow processes and IT solutions are often not in place to effectively document adherence. The On Q Care Planning SystemTM (CPS), an evidence-based patient assessment and care planning software, has been designed to close gaps in quality cancer care and facilitate data collection to help centers both better understand and document their adherence rates to quality care standards. Methods: This multi-site study will enroll approximately 150 non-metastatic breast cancer patients, presenting for no greater than their second medical oncology visit, across five cancer centers. Patients must be planned for but not yet receiving chemotherapy treatment. A between subject design using 150 matched historical controls will be used to assess the impact of the 2-part intervention, at both the patient and provider level, on select quality metrics. At two consecutive clinical visits, patients will engage with the On Q CPS to assess family and medical history and current symptoms and receive two separate care plans. Care plans include (when applicable) recommendations for symptom management and appropriate referrals (i.e. genetic counseling for those at increased hereditary risk, and/or reproductive endocrinology for those interested in preserving fertility). To augment the effectiveness of the On Q CPS, providers will also participate in certified continuing medical education activities designed to educate about evidence-based assessment, decision-making, and management strategies for breast cancer patients. The primary aim is to evaluate provider adherence to select quality metrics among recently diagnosed breast cancer patients following the intervention, and compare to adherence rates for historical controls from the pre-intervention period. Metrics of primary interest include distress screening and management, complete family history assessment, genetic counseling referral, discussion of infertility risk, and discussion of fertility preservation options and/or referral to a specialist. These metrics have been chosen as the primary endpoints given that they have been historically documented as being resistant to change. Outcomes will be assessed by chart abstraction using a score card method of select quality metrics for both enrolled patients and matched historical controls. Analysis/Results: Patient enrollment begins in June 2015 and thus data will be presented at time of symposium. Patient characteristics and primary outcomes will be analyzed using a multi-step approach to first describe and then compare, at the individual patient level, provider adherence to the select quality metrics evaluated in this study. Descriptive statistics will also be estimated within a mixed model approach for the rate with which each single metric was achieved across patients. Conclusions: The On Q CPS, a care planning software tool, has the potential to both improve provider adherence to NQS and allow institutions an easy and accessible way to document that adherence. Citation Format: Hathaway A, Halilova K, Gaguski ME, Thomas K, Dudley WN, Stricker CT, Hammelef KJ, Panzer SL, Rocque GB. Improving provider adherence to breast cancer care quality metrics: Use of a novel care planning tool. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-16.

#1120 Purpose: Arthralgia is a common clinical phenomenon seen in postmenopausal women receiving aromatase inhibitors (AI). This study aims to evaluate the perceived onset, prevalence, and risk factors for AI-related arthralgia.&#x2028; Patients and Methods: We performed a cross-sectional analysis of a cohort of postmenopausal women with stage I-III breast cancer receiving adjuvant AI therapy at an outpatient breast oncology clinic at a large university hospital. Patient-reported symptoms and attribution of AI as a cause of arthralgia were main outcomes. Multivariate logistic regression analyses were performed to assess risk factor(s).&#x2028; Results: 300 patients have been enrolled, with a mean age of 61 +/- 10 years, 84% White, and 38(13%) Black. A total of 173 (58%) reported AI-related arhtralgia during the course of AI treatment and 139 (47%) attributed AI as a cause of their current arthralgia. While 103 (34%) reported having “arthritis” prior to AI initiation, 13% reported onset of symptoms within 1 month of medication initiation, 42% between 1-3 months, 27% between 3-6 months, 12% between 6-12 months, and 20% after 12 months. In a multivariate logistic regression model, time since last menstrual period (LMP) was the only significant predictor of reporting AI-related arthralgia; age, race, employment status, chemotherapy, and weight gain since breast cancer were not associated with the clinical syndrome. Controlling for these covariates, those who had LMP within 5 years had the highest probability of reporting AI-related arthralgia (73%), while those with LMP beyond 10 years had the lowest (35%), p=0.017. Prior arthritis was unrelated to AI-related arthralgia either in univariate or multivariate analyses.&#x2028; Conclusions: AI-related arthralgia is common and appears to be inversely related to the length of time since cessation of menstrual function. These findings suggest that estrogen withdrawal may compound these symptoms and may play a role in the mechanism of this disorder. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1120.

Introduction: Survivorship care plans (SCPs) have been suggested as a solution to the fragmentation of care and suboptimal outcomes experienced by the more than 13 million cancer survivors in the US. Provider and patient acceptance of SCPs is generally high, but trials to date have examined outcomes such as cancer-related distress rather than constructs more directly related to the purpose of SCPs, such as improving coordination of care, knowledge about survivorship issues, and perceived usefulness by patients. Moreover, little is known about processes by which SCPs are developed and delivered in practice – who is involved and the level of resources needed for implementation. This pilot study used a quasi-experimental, pre-test/post-test design to examine the process of delivering standardized SCPs and the outcomes achieved by post-treatment breast cancer survivors at seven cancer centers affiliated with the LIVESTRONG™ Survivorship Centers of Excellence Network. Method: Outcomes were assessed prior to SCP delivery and 3 months following and included survivors’ use of and satisfaction with SCPs, perceived knowledge about survivorship care and potential late effects, and survivors’ assessment of the quality and coordination of survivorship care. Process variables included type of provider delivering the SCP and time required to complete and deliver the SCP. Results: 139 breast cancer survivors completed baseline and follow-up measures and received a comprehensive, standardized SCP at a survivorship visit (Age M = 53.9 years, 3.4 years post-diagnosis, 90.6% Caucasian). Satisfaction with the SCP was high, with 90% of participants being at least ‘satisfied’ and 56% being ‘very’ or ‘extremely satisfied’. Perceived knowledge about survivorship care improved following SCP delivery (p &lt; 0.001), as did survivor perception of quality of survivorship care received and coordination among providers (all p &lt; 0.001). A trend toward improvement in satisfaction with the follow-up care provider was also noted (p = 0.11). Most participants (88%) reported reading their SCP carefully following delivery. In the 3 months following delivery, participants reported they most commonly used SCP materials to make decisions about appropriate exercise (69%), which tests to receive and when (65%), and to make dietary changes (65%), but only 23% shared the SCP with their primary care providers during that time frame. With respect to process, providers were predominately NPs and Pas (80%). Although implementation varied, time burden was consistently high (M = 72 minutes to prepare, M = 48 minutes to deliver). Discussion: This is the first known study to demonstrate significant improvements in perceived knowledge regarding and perceived quality of survivorship care following receipt of a comprehensive SCP. Survivors were satisfied with their SCP, and most frequently reported using SCPs in making decisions regarding behavioral changes. Results warrant further consideration in a randomized controlled trial, and approaches that maximize efficiency are needed given the time burden of providers to provide an SCP. SCPs have been recommended for all cancer survivors and these data provide preliminary support for this recommendation. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-08-02.